Metastatic adamantinoma responds to treatment with receptor  tyrosine kinase inhibitor.
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Arkadiusz Z
AZ
Dudek
Pradeep K
PK
Murthaiah
Michael
M
Franklin
Alexander M
AM
Truskinovsky
D000063:Accidents, Traffic; D050398:Adamantinoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001064:Appendicitis / Q000150:complications; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005528:Foot / Q000473:pathology; D050723:Fractures, Bone / Q000150:complications; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications; D011758:Pyrroles / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012907:Smoking; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D014806:Vitamin B 12 Deficiency / Q000150:complications
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D020794:Receptor Protein-Tyrosine Kinases; D000077210:Sunitinib